All In Biotech

Free tool

FAERS Monitor: Detrol

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020771 or its brand name (Detrol, Tolterodine Tartrate). Reports on generic versions are filed under their own applications.

Reports

8,980

Serious

5,709

64% of reports

Hospitalization

2,688

Death reported

551

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective882
  • fatigue586
  • fall580
  • nausea532
  • dizziness466
  • headache449
  • asthenia437
  • diarrhoea416
  • pain401
  • urinary tract infection377
  • dyspnoea375
  • constipation322
  • vomiting311
  • weight decreased307
  • arthralgia306

Reports by year received

View as table
YearReports
2004383
2005519
2006455
2007369
2008408
2009420
2010600
2011474
2012537
2013294
2014498
2015465
2016488
2017454
2018446
2019481
2020373
2021267
2022276
2023184
2024249
2025202
2026136

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,179 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
urinary tract infectionSignal3775.24.71,277
fallSignal5804.13.81,369
constipationSignal3223.53.1566
astheniaSignal4372.72.5483
weight decreasedSignal3072.62.3298
dizzinessSignal4662.22.0307
fatigue5861.81.6200
arthralgia3061.71.594
headache4491.71.5126
nausea5321.61.5115
drug ineffective8821.61.5193
dyspnoea3751.61.475
vomiting3111.51.461
pain4011.51.475
diarrhoea4161.51.473

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.